From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs

• Published in: Molecules (Basel, Switzerland) Switzerland), 2023-08, Vol.28 (17), p.6329
• Main Authors: Nordio, Giulia, Piazzola, Francesco, Cozza, Giorgio, Rossetto, Monica, Cervelli, Manuela, Minarini, Anna, Basagni, Filippo, Tassinari, Elisa, Dalla Via, Lisa, Milelli, Andrea, Di Paolo, Maria Luisa
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; antiproliferative activity; Biogenic amines; docking studies; Enzymes; inhibitors; LN-229 cells; Monoamine oxidase; monoamine oxidases; Nitrogen; polyamine analogs; Polyamines; Prostate cancer
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules28176329

Monoamine oxidases (MAOs) are well-known pharmacological targets in neurological and neurodegenerative diseases. However, recent studies have revealed a new role for MAOs in certain types of cancer such as glioblastoma and prostate cancer, in which they have been found overexpressed. This finding is opening new frontiers for MAO inhibitors as potential antiproliferative agents. In light of our previous studies demonstrating how a polyamine scaffold can act as MAO inhibitor, our aim was to search for novel analogs with greater inhibitory potency for human MAOs and possibly with antiproliferative activity. A small in-house library of polyamine analogs (2–7) was selected to investigate the effect of constrained linkers between the inner amine functions of a polyamine backbone on the inhibitory potency. Compounds 4 and 5, characterized by a dianiline (4) or dianilide (5) moiety, emerged as the most potent, reversible, and mainly competitive MAO inhibitors (Ki < 1 μM). Additionally, they exhibited a high antiproliferative activity in the LN-229 human glioblastoma cell line (GI50 < 1 μM). The scaffold of compound 5 could represent a potential starting point for future development of anticancer agents endowed with MAO inhibitory activity.